

Understanding Lymphoma: Adult T-Cell Leukemia/Lymphoma

Adult T-cell leukemia/lymphoma (ATLL) is a rare T-cell lymphoma that can be found in the blood (leukemia), lymph nodes (lymphoma), skin, or multiple other areas of the body.

Symptoms vary depending on the different ATLL subtypes (described below). The most common symptoms are:

- Skin rash
- Swollen lymph nodes (bean-shaped structures that help the body fight infections, Figure 1)
- Swollen liver or spleen
- Fever
- Night sweats
- Weight loss




There are four subtypes of ATLL:

- Acute.
- Lymphoma
- Chronic
- Smoldering

The acute and lymphoma subtypes are aggressive (fast-growing) forms of ATLL, whereas chronic and smoldering are indolent (slow-growing).

• Acute: Symptoms develop rapidly and may include fatigue (extreme tiredness), skin rash, and enlarged lymph nodes in the neck, underarm, or groin. The characteristics of acute ATLL are a high level of white blood cells (cells that help the body fight infections and cancer) often with hypercalcemia (elevated calcium levels in the blood), which can cause confusion, irregular heartbeat, and severe constipation (a



condition in which stool becomes hard, dry, and difficult to pass, and bowel movements don't happen very often). Acute ATLL may spread to extranodal tissues (tissues outside the lymph nodes).

- **Lymphoma:** This aggressive type of ATLL is found primarily in the lymph nodes, causes swollen or enlarged lymph nodes, and may cause skin rash, hypercalcemia (high levels of calcium in blood), and an increase in the level of white blood cells.
- **Chronic:** This slow-growing type of ATLL can result in elevated lymphocytes in the blood, enlarged lymph nodes, skin rash, or fatigue. It can also be found in other areas of the body such as the spleen and liver.
- **Smoldering:** This slow-growing type of ATLL is associated with very mild symptoms such as a few skin lesions and/or rash.

Depending on the subtype, diagnosing ATLL will require a biopsy. During this procedure, a needle is used to take a small sample of the affected tissue, which is then observed under a microscope. A blood test (a sample of blood collected to measure the amount of certain molecules in the blood or to count blood cells) will also be necessary to measure the number of white blood cells, calcium levels, and the presence of the HTLV-1 virus. Other tests, such as a bone marrow (the spongy tissue inside the bones) biopsy; a computed tomography (CT) scan of the chest, abdomen, liver, and spleen; and/or a positron emission tomography (PET, an imaging scan that uses a special dye to locate the cancer in the body) scan, may be used to determine where the cancer is located.

O TREATMENT OPTIONS

For some patients who have one of the slower-growing subtypes of ATLL with mild or no symptoms, physicians may recommend to not treat the disease right away. This is called active surveillance (also known as "watchful waiting" or "observation"). In this case, patients' overall health and disease are monitored through regular physical exams (to check for any swollen lymph nodes) or periodic imaging tests ([CT] scans). If patients begin to have symptoms or signs of disease progression, treatment is initiated. For more information about active surveillance, please see the *Active Surveillance* publication on Lymphoma Research Foundation's website (**lymphoma.org/publications**).

For ATLL affecting the skin, skin-directed therapies (for example, topical [applied to the skin surface] steroids or local radiation [applied only to the affected area in the body]) may be prescribed. Because ATLL is such a rare disease, there have not been enough patients enrolled in clinical trials (a type of research study that tests how well new treatments work) to establish treatment standards (the proper treatment that is widely used by health care professionals and accepted by medical experts) in the United States and Europe, especially for the acute and lymphoma subtypes. As a result, common frontline (initial) therapies used to treat ATLL are the same as those used to treat other types of T-cell lymphomas. These include:

- CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
- CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone)
- Dose-adjusted EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone)
- Hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) alternating with high-dose methotrexate and cytarabine (Cytosar)
- BV-CHP (Brentuximab vedotin [Adcetris] + CHP [cyclophosphamide, doxorubicin, and prednisone]) for lymphomas that are positive for CD30 (molecule present on the surface of certain lymphomas)
- Zidovudine (Retrovir, AZT) in combination with interferon alfa to treat the underlying HTLV-1 infection (in patients with slow-growing ATLL)

VCAP-AMP-VECP (vincristine, cyclophosphamide, doxorubicin, prednisone, ranimustine, vindesine, etoposide, and carboplatin) is a regimen tested in Japan.

In some patients, stem cell transplantation (SCT) may be appropriate following remission (disappearance of signs and symptoms). During this procedure, the patient is treated with high-dose chemotherapy or radiation and then receives healthy autologous (patient's own cells) or allogeneic (cells from a related or unrelated donor) stem cells to restore the immune system and the bone marrow's ability to make new blood cells. Patients seeking more information about SCT should view the Understanding Cellular Therapy guide on LRF's website (lymphoma.org/publications).

Similar to frontline treatment, standard treatment for relapsed (disease returns after treatment) ATLL has not been established. Many regimens used to treat other T-cell lymphomas following relapse are also being used to treat ATLL, including the following:

- DHAP (dexamethasone, cytarabine, and cisplatin)
- ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin)
- GDP (gemcitabine, dexamethasone, and cisplatin)
- ICE (ifosfamide, carboplatin, and etoposide)
- Pralatrexate (Folotyn)
- Belinostat (Beleodaq)

Q TREATMENTS UNDER INVESTIGATION

Several new drugs are being studied in clinical trials for ATLL as single-agent (one drug) therapy or as part of a combination (two or more drugs) therapy regimen, including the following:

- Bortezomib (Velcade)
- Tolinapant (ASTX660)
- Lenalidomide (Revlimid)
- Valemetostat (DS-3201b)

It is critical to remember that today's scientific research is always evolving. Treatment options may change as new treatments are discovered and current treatments are improved. Therefore, it is important that patients check with their physician or with the LRF for any treatment updates that may have recently appeared.

CLINICAL TRIALS

Clinical trials are crucial in identifying effective drugs and the best treatment doses for patients with lymphoma. Because ATLL is a rare disease, clinical trial enrollment is critical for establishing more effective, less toxic treatments. The rarity of the disease also means that the latest treatments are often available only through clinical trials. Patients interested in participating in a clinical trial should view the *Understanding Clinical Trials* fact sheet (**lymphoma.org/publications**) and the *Clinical Trials Search Request Form* (**lymphoma.org**), talk to their physician, or contact the LRF Helpline for an individualized clinical trial search by calling (800) 500-9976 or emailing helpline@lymphoma.org.



Patients with lymphoma should have regular visits with their physician. During those visits, medical tests (such as blood tests and CT/PET scans) may be required at various times during remission to evaluate the need for additional treatment.

Some treatments can cause side effects that are long-term (occur **during** treatment and continue for months or years) or late side effects (appear only months, years, or decades **after** treatment has ended). These side effects can vary depending on the following factors:

- Duration of treatment (how long the treatment was given)
- Frequency of treatment (how often the treatment was administered)
- Type of treatment given
- · Age and gender of the patient
- Patient overall health at the time of treatment

A physician will check for these side effects during follow-up care. Visits may become less frequent the longer the patient stays in remission.

Patients and their caregivers are encouraged to keep copies of all medical records. This includes test results as well as information on the types, amounts, and duration of all treatments received. Medical records are important for keeping track of any side effects resulting from treatment or potential disease recurrences. LRF's award-winning Focus on Lymphoma mobile app (lymphoma.org/mobileapp) or our Lymphoma Care Plan (lymphoma.org/publications) can help patients manage this documentation.



Keeping your information in one location can help you feel more organized and in control. This also makes it easier to find information pertaining to your care and saves valuable time. LRF's Lymphoma Care Plan document organizes information on your health care team, treatment regimen, and follow-up care. You can also keep track of health screenings and any symptoms you experience to discuss with your health care provider during

LRF appreciates the expertise and review of our Editorial Committee:

Leo I. Gordon, MD, FACP Co-Chair Robert H. Lurie Comprehensive Cancer Center of Northwestern University Kristie A. Blum, MD Co-Chair Emory University School of Medicine Jennifer E. Amengual, MD Columbia University Carla Casulo, MD University of Rochester Medical Center Alex Herrera, MD City of Hope Shana Jacobs, MD Children's National Hospital Patrick Connor Johnson, MD Massachusetts General Hospital Manali Kamdar, MD University of Colorado Ryan C. Lynch, MD University of Washington future appointments. The Lymphoma Care Plan document can be accessed by visiting **lymphoma.org/publications**. LRF also offers a variety of educational activities, including live meetings and webinars, for individuals looking to learn directly from lymphoma experts. To view our schedule of upcoming programs, please visit **lymphoma.org/programs**.

LRF Helpline

The LRF Helpline staff are available to answer your general questions about lymphoma and treatment information, as well as provide individual support and referrals to you and your loved ones. Callers may request the services of a language interpreter. LRF also offers a one-to-one peer support program called the Lymphoma Support Network and clinical trials information through our Clinical Trials Information Service. For more information about any of these resources, visit our website at **lymphoma.org**, or contact the LRF Helpline at **(800) 500-9976** or **helpline@lymphoma.org**.

Para información en Español, por favor visite **lymphoma.org/es**. (For Information in Spanish, please visit lymphoma.org/es).

LRF FOCUS ON LYMPHOMA MOBILE APP

Focus on Lymphoma is the first app to provide patients and their caregivers with tailored content based on lymphoma subtype and actionable tools to better manage diagnosis and treatment. It provides convenient and comprehensive lymphoma management in one secure and easy-to-navigate app, no matter where you are on the care continuum. Get the right information, first, with resources from the entire Lymphoma Research Foundation content library, use unique tracking and reminder tools, and connect with a community of specialists and patients. To learn more this resource, visit our website at **lymphoma.** org/mobileapp, or contact the LRF Helpline at 800-500-9976 or helpline@lymphoma.org.

Peter Martin, MD Weill Cornell Medicine Neha Mehta-Shah, MD, MSCI Washington University School of Medicine in St. Louis M. Lia Palomba, MD Memorial Sloan Kettering Cancer Center Pierluigi Porcu, MD Thomas Jefferson University Sarah Rutherford, MD Weill Cornell Medicine **Contact LRF:** Helpline: (800) 500-9976 Email: helpline@lymphoma.org

www.lymphoma.org

Supported through grants from: I Bristol Myers Squibb Genentech

The Understanding Lymphoma fact sheet series is published by the Lymphoma Research Foundation (LRF) for the purpose of informing and educating readers. Facts and statistics were obtained using published information, including data from the Surveillance, Epidemiology, and End Results (SEER) Program. Because each person's body and response to treatment is different, no individual should self-diagnose or embark upon any course of medical treatment without first consulting with his or her physician. The medical reviewer, the medical reviewer's institution, and LRF are not responsible for the medical care or treatment of any individual.